v3.25.2
License and Research and Development Agreements - Additional Information (Details) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
Jun. 30, 2025
Feb. 28, 2023
Aug. 31, 2022
Mar. 31, 2022
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Research and development expense         $ 7,509,000 $ 37,458,000 $ 38,146,000 $ 67,961,000  
Accrued clinical and research and development expenses $ 277,000       277,000   277,000   $ 12,521,000
Stanford License                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Upfront payment     $ 50,000            
Issuance of common shares for license, shares     67,605            
Issuance of common shares for license, fair value     $ 100,000            
Research and development expense     200,000   0 0 0 0  
Stanford License | Maximum                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Annual license maintenance fees     100,000            
Stanford License | Maximum | Development Milestones                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Milestone payments     4,000,000            
Stanford License | Maximum | Sales Milestones                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Milestone payments     $ 7,500,000            
Oxford License and Supply Agreement                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Research and development expense         500,000 0 500,000 0  
2022 NCI License                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Research and development expense         0 0   100,000  
Amount paid in connection with achievement of change in control milestone             200,000    
Future obligations under 2022 NCI license 0       0   $ 0    
Payment of extension royalty       $ 50,000          
Termination and expiration clause             In June 2025, the Company and the NCI reached an agreement about the amounts payable under the 2022 NCI License, including $0.2 million to be paid in connection with the achievement of the change in control milestone. Upon NCI's receipt of the agreed upon amounts, the 2022 NCI License was terminated. The Company paid $0.2 million as of June 30, 2025 and has no future obligations under the 2022 NCI License.    
2022 NCI License | Maximum                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Research and development expense             $ 100,000    
Milestone payments 200,000                
2023 NCI License                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Research and development expense         0 $ 0      
Non-refundable license fee   $ 300,000              
Accrued clinical and research and development expenses                 $ 100,000
Minimum payment on sale, transfer or lease of PRV   5,000,000              
Termination and expiration clause             Unless earlier terminated, the 2023 NCI License would expire upon the expiration of the last to expire of the licensed patent rights. The NCI may terminate or modify the 2023 NCI License in the event of an uncured material breach, including, but not limited to, if the Company does not meet certain milestones by certain dates, or upon certain insolvency events that remain uncured following the date that is 90 days following written notice of such breach or insolvency event. The Company may terminate the license, or any portion thereof, at its sole discretion at any time upon 60 days written notice to the NCI.In June 2025, the Company and the NCI reached an agreement (“Settlement Agreement”) about the amounts payable under the 2023 NCI License including $0.1 million to be paid under in connection with the achievement of the change in control milestone. Under the terms of the Settlement Agreement, the 2023 NCI License will terminate on the earlier of: (1) July 31, 2025 (subsequently amended to September 15, 2025 – see Note 12); (2) the voluntary termination of the 2023 NCI License by the Company; or (3) the date of the license transfer to the third party (“License Assignment”), subject to approval by the NCI. As of June 30, 2025, the Company has no future obligations under the 2023 NCI License besides unbilled patent expenses related to the 2023 NCI License incurred by the NCI from January 2025 through the termination of the 2023 NCI License or the License Assignment, which are expected to be immaterial. If the License Assignment occurs, the Company will be required to pay an assignment royalty fee of $0.1 million to the NCI and will be relieved from unbilled patent expenses related to the 2023 NCI License incurred in 2025.    
Payment of reimburse in expense incurred on patent   100,000              
2023 NCI License | Research and Development                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Non-refundable license fee   400,000              
2023 NCI License | License Assignment                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Minimum annual royalty payments 100,000                
2023 NCI License | Besides Unbilled Patent Expenses                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Future obligations under 2022 NCI license 0       $ 0   $ 0    
2023 NCI License | Maximum                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Research and development expense             $ 100,000 $ 100,000  
2023 NCI License | Maximum | Development Milestones                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Milestone payments   1,700,000              
2023 NCI License | Maximum | Regulatory Milestones                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Milestone payments $ 100,000 100,000              
2023 NCI License | Maximum | Sales Milestones                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Milestone payments   16,000,000              
2023 NCI License | Minimum                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Minimum annual royalty payments   50,000              
Minimum payment on submission of PRV   $ 500,000              
Stanford University | Stanford License                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Issuance of common shares for license, shares     22,317            
Non-profit Organizations | Stanford License                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Issuance of common shares for license, shares     27,100            
Stanford University Inventors | Stanford License                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Issuance of common shares for license, shares     18,188            
Commercial Milestone Event | Stanford License | Maximum                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Milestone payments     $ 50,000            
Certain Additional Milestone Events | Stanford License | Maximum                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Milestone payments     $ 500,000